<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Liraglutide is a GLP-1 receptor <z:chebi fb="4" ids="48705">agonist</z:chebi>, a novel medication for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We describe a case of <z:mpath ids='MPATH_691'>pustules</z:mpath> in a patient recently started on liraglutide </plain></SENT>
<SENT sid="2" pm="."><plain>Common side effects of liraglutide are <z:e sem="disease" ids="C0017178" disease_type="Disease or Syndrome" abbrv="">gastrointestinal disorders</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Skin and tissue reactions are less well-known side effects </plain></SENT>
<SENT sid="4" pm="."><plain>Liraglutide could be the cause of <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">skin eruptions</z:e> in this patient, possibly by immunogenicity </plain></SENT>
</text></document>